Archive for L/D-aminopterin

Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial for the treatment of Psoriasis with (L/D)-Aminopterin

Congratulations to Syntrix scientists on their new grant for $1.725M from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).  The project title is “Efficacy and Resistance Mechanisms of (L/D)-Aminopterin in Psoriasis.”  Here is the public health relevance from the proposal:  “Psoriasis is a chronic scaly and inflammatory […]

Syntrix Presents at the 2009 NCI SBIR Investor Forum in Boston

Syntrix was one of 14 breakthrough technology companies invited to present at the 2009 SBIR Investor Forum sponsored by the National Cancer Institute (NCI). The chosen companies were selected from a highly competitive field of applicants by an independent panel of experts from venture capital firms, bio-pharmaceutical and medical device companies, based on their strength of research, impact on […]

New Syntrix Publication: Pharmacodynamic Properties of Methotrexate and Aminotrexate During Weekly Therapy

Congratulations to Syntrix scientists and collaborators at the University of Medicine and Dentistry of New Jersey for their published paper in Cancer Chemotherapy and Pharmacology. Abstract excerpts: Aminopterin (AMT) has several advantages over the related antifolate methotrexate (MTX), including greater potency, complete oral bioavailability, and greater accumulation by leukemic blasts in vitro. We compared the pharmacodynamic properties of equipotent […]